Campaigners have welcomed “momentous” plans to allow doctors to prescribe cannabis products to patients from November 1.
Home Secretary Sajid Javid has decided to reschedule the products, relaxing the rules about the circumstances in which they can be given to patients, after considering expert advice from a specially commissioned review.
The new regulations follow several high-profile cases, including that of young epilepsy sufferers Alfie Dingley and Billy Caldwell, whose conditions appeared to be helped by cannabis oil.
Alfie’s mother, Hannah Deacon, was one of many campaigners to celebrate the move.
She said: “Today is a momentous day for every patient and family with a suffering child who wish to access medicinal cannabis.
“We urge the medical world to get behind these reforms so they can help the tens of thousands of people who are in urgent need of help.
“I have personally seen how my son’s life has changed due to the medical cannabis he is now prescribed.
“As a family we were facing his death. Now we are facing his life, full of joy and hope which is something I wish for each and every person in this country who could benefit from this medicine.”
Professor Mike Barnes, the medical cannabis expert who secured its first long-term licence for Alfie, said: “This announcement has transformed the position of the UK in this exciting and developing field.
“Many of my medical colleagues are understandably unsure about the benefits.
“After all, medical cannabis has been illegal in the UK for generations. But I urge them to embrace these developments.
“Compared to many pharmaceutical drugs, whole plant medical cannabis products are remarkably safe and, as recent high-profile cases have shown, can produce dramatic improvements for patients.”
The new law will not limit the types of conditions that can be considered for treatment and it means doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines.
Mr Javid said: “Having been moved by heartbreaking cases involving sick children, it was important to me that we took swift action to help those who can benefit from medicinal cannabis.
“We have now delivered on our promise and specialist doctors will have the option to prescribe these products where there is a real need.
“I’m grateful to the expert panel – who have been considering cases in the interim – and to those who’ve worked hard to bring about this change at the earliest possible opportunity.”
Billy Caldwell’s mother, Charlotte Caldwell, said she was crying tears of joy at the announcement.
She said: “It’s been a treasure just out of reach for what seems like forever, but to see it in writing from the Government is incredible.
“This isn’t about Billy and me, it’s about a nation.
“Only relatively recently did our Government and country really start to appreciate just how many wee children and people of all ages were affected by the difficulties associated with accessing medicinal cannabis.
“But once it became clear that it wasn’t just about what was perceived to be a small number of very sick children, and that medicinal cannabis could make a life-changing or life-saving difference to more than a million people, the overwhelming support of the public and the incredible speed of reaction of the Home Secretary has delivered an utterly amazing result.
“What started out as a journey for me as Billy’s mummy to help my little boy has become something much bigger.”
An initial review by chief medical adviser Dame Sally Davies concluded that there is evidence medicinal cannabis has therapeutic benefits.
The Advisory Council on the Misuse of Drugs (ACMD), which carried out the second part of the review, recommended cannabis-derived medicinal products should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.
Cannabis has previously been classed as a Schedule 1 drug, meaning it is thought to have no therapeutic value but can be used for the purposes of research with a Home Office licence.
However the decision to prescribe these unlicensed medicines must still be made by a specialist doctor – not a GP.
They can make decisions on prescribing cannabis-based products for medicinal use on a case-by-case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products.
Mr Javid said that to constitute a cannabis-based product for medicinal use, three requirements must be satisfied.
These are that it “needs to be a preparation or product which contains cannabis, cannabis resin, cannabinol or a cannabinol derivative; it is produced for medicinal use in humans and; is a medicinal product, or a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product”.
Setting out the new regulations, Mr Javid added: “This brings these products explicitly into the existing medicines framework.
“These regulations are not an end in themselves. The ACMD will be conducting a long-term review of cannabis and the National Institute for Health and Care Excellence (Nice) has been commissioned to provide advice for clinicians by October next year.
“The Government will monitor the impact of the policy closely as the evidence-base develops and review when the ACMD provides its final advice.”
Sir Mike Penning, co-chairman of the cross-party parliamentary group on Medical Cannabis Under Prescription, welcomed the move but said there had been a “disappointing reaction” from many health professionals so far.
“This formal announcement makes this a momentous day and I commend the Home Secretary for taking these bold and decisive steps,” he said.
“It has reversed decades of backward thinking on this important issue by successive governments. There is still much detailed work to be done.
“Since the high-profile cases of the summer involving the young children with epilepsy there has been a very disappointing reaction from a large number of consultants and health trusts, with many refusing to even submit applications to the interim medical cannabis expert panel.
“Today’s announcement puts the ball now firmly in the court of the health professionals and health authorities to approach this new and exciting field of UK medicine with an open mind.”